Serum Uric Acid Levels in Multiple Sclerosis: A Case Control Study
Abstract
Background: Oxidative stress contributes to multiple sclerosis (MS) pathogenesis, and serum uric acid (SUA) is a potent endogenous antioxidant. Serum uric acid (SUA), have therefore become a topic of scientific interest due to their potential modulatory role in CNS injury including multiple sclerosis.
Methods: In this case–control study, 44 patients with MS and 44 age- and sexmatched healthy controls were evaluated. SUA levels were measured using enzymatic methods. Associations between SUA levels and demographic variables, disability (Expanded Disability Status Scale, EDSS), disease duration, ambulation status, and disease-modifying therapies (DMTs) were analyzed using ANOVA and regression models adjusted for age, sex, and renal function.
Results: MS patients exhibited significantly lower SUA levels compared to healthy controls (p < 0.05). SUA levels were not significantly associated with EDSS scores, disease duration, or ambulation status. While DMT exposure influenced SUA levels overall, no significant pairwise differences were observed between specific drugs.
Conclusion: These findings support the potential utility of SUA as a diagnostic biomarker in MS and as a marker of treatment response to DMTs. However, SUA levels do not correlate with disease duration or physical disability (EDSS).
Downloads
References
Hooper DC, Scott GS, et al. Uric acid, a peroxynitrite scavenger, protects against CNS inflammation. Proc Natl Acad Sci U S A. 1998;95(2):675–680.
Toncev G, Milicic B, et al. Serum uric acid levels in patients with multiple sclerosis. Clin Chem Lab Med. 2002;40(4):361–363.
Spitsin S, Scott GS, et al. Reduction of inflammation using uric acid in experimental allergic encephalomyelitis. J Neuroimmunol. 2001;113(1):1–7.
Rentzos M, Nikolaou C, Anagnostouli M, et al. Serum uric acid and multiple sclerosis. Clin Neurol Neurosurg. 2006;108(6):527–531.
Peng F, Zhang B, et al. Serum uric acid levels and multiple sclerosis: a meta-analysis. Neurol Sci.
;36(6):921–927.
Keegan BM, Noseworthy JH. Multiple sclerosis: pathophysiology and clinical features. Clin Neuropharmacol. 2002;25(2):93–105.
Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. N Engl J Med. 2020;383(18):1693–1704.
Müller T, et al. Influence of immunomodulatory therapies on uric acid metabolism in MS. J Neurol Sci. 2014;347(1–2):1–5.
Lassmann H. Mechanisms of white matter damage in multiple sclerosis. Glia. 2014;62(11):1816– 1830.
Lanzillo R, et al. Uric acid in relapsing-remitting multiple sclerosis: relation to disability and MRI lesions. Neurol Sci. 2017;38(1):81–86.
Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–173.
Moccia M, Lanzillo R, Palladino R, et al. Uric acid: a potential biomarker of multiple sclerosis and of its disability. Clin Chem Lab Med. 2015;53(5):753–759.
Schreibelt G, van Horssen J, van Rossum S, et al. Therapeutic potential and biological role of endogenous antioxidant enzymes in multiple sclerosis pathology. Brain Res Rev. 2007;56(2):322– 330.
Zoccolella S, Tortorella C, Iaffaldano P, et al. Low serum urate levels are associated to female gender in multiple sclerosis patients. PLoS One. 2012;7(7):e40608.
Toncev G, Milicic B, Toncev S, Samardzic G. Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol. 2002;9(3):221–226.
Candan F, et al. The relationship between multiple sclerosis and endogenous antioxidant serum uric acid. Turk J Neurol. 2007;13(6):409–414.
Constantinescu CS, Freitag P, Kappos L. Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis. Mult Scler. 2000;6(6):378–381.
Toncev G, Vesic K, Aleksic D, Lazarevic S. Higher serum uric acid levels in multiple sclerosis patients after longterm interferon beta treatment. Serb J Exp Clin Res. 2016;18(3):227–230.
Guerrero AL, Martín-Polo J, Laherrán E, et al. Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment. Eur J Neurol. 2008;15(4):394–397.
=
Author(s) and co-author(s) jointly and severally represent and warrant that the Article is original with the author(s) and does not infringe any copyright or violate any other right of any third parties, and that the Article has not been published elsewhere. Author(s) agree to the terms that the GPH Journal will have the full right to remove the published article on any misconduct found in the published article.
